TNF and rheumatoid arthritis: In the 3‐year ORAL Surveillance study on tofacitinib in rheumatoid arthritis (RA), the risk of malignancy was slightly higher with tofacitinib compared to TNF inhibitors (1.13 vs. 0.77 events per 100 patient‐years).